Fosamax (Alendronate): What Changes If You Have Never Taken It vs. Already Have

Why Your Treatment History Is the First Clinical Question

Before your clinician writes a single prescription, the most consequential question is not which bisphosphonate to choose. It is whether you have ever taken one before. That single answer changes your expected BMD trajectory, fracture risk reduction timeline, and how your prescriber should interpret your first follow-up DEXA scan.

Alendronate works by binding tightly to hydroxyapatite in bone and inhibiting osteoclast-mediated resorption. Bisphosphonates accumulate in the skeleton with repeated dosing, meaning a woman who took Fosamax for four years and then stopped for two years is pharmacologically different from a woman who has never swallowed the drug. Her bone reservoir still contains residual drug; her osteoclast suppression never fully reset to baseline.

This distinction matters for three practical reasons: the speed of your initial BMD response, the urgency of restarting after a break, and how your prescriber interprets a "flat" DEXA result.

What Drug-Naive Means Clinically

Drug-naive means you have never received any bisphosphonate, oral or intravenous, for any indication, including Fosamax, Actonel (risedronate), Boniva (ibandronate), or Reclast (zoledronic acid). A prior course of denosumab or raloxifene does not make you "bisphosphonate-experienced" because those drugs act through entirely different mechanisms.

What Treatment-Experienced Means Clinically

Treatment-experienced means you have completed at least one prior course of a bisphosphonate, whether you are restarting after a planned drug holiday, switching back from another agent, or resuming after a lapse in coverage or adherence. Subcategories matter here:

• Completed 5-year course with planned holiday, now restarting
• Stopped early (adverse effect, non-adherence) with under-loaded skeletal reservoir
• Switched from IV zoledronic acid and transitioning to oral alendronate

Each subcategory has a slightly different restart rationale, covered below.

Drug-Naive Women: Dose, Expected Response, and Life-Stage Differences

If you have never taken a bisphosphonate, alendronate's dose is anchored to your fracture-risk category and menopausal status, not to your BMD T-score alone.

Standard Dosing for Drug-Naive Post-Menopausal Women

The approved treatment dose for post-menopausal osteoporosis is 70 mg once weekly, taken with 6 to 8 ounces of plain water, at least 30 minutes before any food, drink, or other medication, in the upright position. The 10 mg daily formulation is pharmacologically equivalent but is now rarely prescribed because once-weekly dosing produces identical efficacy with meaningfully better adherence.

For prevention in drug-naive post-menopausal women with osteopenia (T-score between -1.0 and -2.5) and moderate FRAX risk, the label supports 35 mg once weekly or 5 mg daily. The distinction between prevention and treatment dosing is not always explained clearly to patients, but it translates to a real difference in the speed of BMD gain.

What Drug-Naive Women Can Expect from the Fracture Intervention Trial

The Fracture Intervention Trial (FIT) is the foundational efficacy dataset for alendronate in post-menopausal women. Over three years, drug-naive women assigned to alendronate saw lumbar spine BMD increase by approximately 8.8% versus placebo, femoral neck BMD by about 3.7%, and a 47% relative risk reduction in morphometric vertebral fractures in the FIT vertebral fracture arm. These are gains from a completely naive skeleton, with no prior osteoclast suppression.

In year one alone, drug-naive women typically gain 5 to 6% at the lumbar spine, with gains decelerating in years two and three as a new bone remodeling equilibrium is reached. If your first follow-up DEXA at 12 to 24 months shows less than a 3% lumbar spine gain, your clinician should investigate adherence, calcium and vitamin D adequacy, secondary causes of bone loss, and absorption issues before concluding the drug is not working.

Premenopausal Drug-Naive Women: A Narrower Indication

Most premenopausal women should not be on alendronate. The drug is not FDA-approved for premenopausal osteoporosis, and evidence for its use in this group is limited to specific conditions: glucocorticoid-induced osteoporosis, anorexia nervosa with severe bone loss, and certain cases of hypothalamic amenorrhea or premature ovarian insufficiency.

Premenopausal drug-naive women with PCOS who also have low BMD from hyperandrogenism, chronic anovulation, and poor bone accrual represent a small but real subgroup where bisphosphonate use may be discussed, though this is largely off-label and requires specialist input. Treating the underlying hormonal disorder first is the standard approach.

Perimenopause: The Transition Window

Perimenopausal women (defined by the STRAW+10 staging system as irregular cycles with FSH elevation) are in a period of accelerating bone loss. Bone loss can reach 2 to 3% per year in the two years around the final menstrual period, far outpacing the 0.5 to 1% annual loss of the stable post-menopausal years.

A drug-naive perimenopausal woman with a T-score already at or below -2.0 may be a candidate for alendronate, though menopausal hormone therapy (MHT) is often the first-line bone-protective strategy in symptomatic perimenopausal women, given its dual role in symptom management and BMD preservation. Alendronate is typically reserved for women who cannot or choose not to use MHT and whose FRAX score places them above the National Osteoporosis Foundation treatment threshold.

Treatment-Experienced Women: Restarting After a Drug Holiday

Planned drug holidays became standard practice after data emerged suggesting that bisphosphonate use beyond 5 years was associated with rare but serious adverse effects, specifically atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ). The FLEX trial (Fracture Intervention Trial Long-term Extension) showed that women who continued alendronate for 10 years versus those who stopped at 5 years had modestly higher spine BMD but similar hip fracture rates, except in the highest-risk subgroup.

The implication: a drug holiday is appropriate for many, but not all, post-menopausal women after 3 to 5 years of treatment.

What Happens to BMD During a Drug Holiday

During a planned holiday, BMD does not immediately crash. The skeleton retains residual alendronate in the mineral matrix, and bone resorption suppression persists for 1 to 3 years after the last dose in most women. This is why alendronate's holiday window is typically 2 to 3 years, longer than risedronate's shorter skeletal retention.

However, BMD does gradually decline during the holiday. The FLEX trial data showed that hip BMD declined by about 2.4% during 5 years off drug in women who had previously been on alendronate, compared with continued slow gain in those who stayed on therapy.

When to Restart: The Clinical Decision Framework

The following framework integrates FLEX data, the American Association of Clinical Endocrinology (AACE) 2020 guidelines, and The Menopause Society's bone health position statement to guide restart decisions for treatment-experienced women:

| Scenario | Holiday Duration | Recommend Restart? | |---|---|---| | T-score at hip still above -2.5, no new fracture | Up to 3 years | Monitor with annual DEXA; restart if T-score drops below -2.5 or fracture occurs | | T-score at hip below -2.5 at any point during holiday | Any | Restart alendronate 70 mg/week or consider IV zoledronic acid | | New clinical fracture during holiday | Any | Restart immediately; reassess for anabolic therapy (teriparatide, romosozumab) first if very high risk | | Stopped early (<3 years) due to GI intolerance | Short course | Skeletal reservoir incompletely loaded; restart with attention to GI tolerability (IV alternative if needed) | | Stopped early due to non-adherence | Short course | Restart 70 mg/week with adherence support; consider once-yearly IV alternative |

The AACE/ACE 2020 clinical practice guidelines recommend reassessing fracture risk after 3 to 5 years of bisphosphonate therapy to guide the holiday decision, with higher-risk women (femoral neck T-score below -2.5 or prior hip or spine fracture) remaining on therapy continuously.

Dose When Restarting

There is no dose escalation for restarting. Treatment-experienced women restart at the standard 70 mg once-weekly treatment dose, not a loading dose. This is a frequent point of confusion: alendronate has no approved loading dose protocol. You do not restart at 140 mg for the first month.

The expected BMD response on restart is typically slower than in the drug-naive first course. Because the skeleton's surface area available for new drug binding is partially saturated with residual drug, the incremental early BMD gain is more modest. A gain of 2 to 4% at the lumbar spine over 12 months on restart is clinically meaningful; do not interpret a smaller number than the first-course gain as treatment failure without context.

Sex-Specific Physiology: How Hormonal Status Changes Everything

Alendronate's pharmacokinetics in women are not simply "the same as men but smaller." Several sex-specific factors affect drug uptake, tolerability, and efficacy.

Estrogen Status and Osteoclast Activity

Estrogen deficiency is the primary driver of post-menopausal bone loss because estrogen normally suppresses osteoclastogenesis and promotes osteoclast apoptosis. When estrogen falls at menopause, osteoclast activity surges, creating more active remodeling sites and faster bone resorption. Alendronate binds to these active remodeling surfaces and blocks osteoclast attachment. The higher the remodeling rate (as in early post-menopause), the more binding sites are available and the faster the initial BMD response.

This is why drug-naive women in the first 2 to 5 years post-menopause often show the most dramatic early BMD gains: their remodeling rate is high, so alendronate has more targets. Women 20 years post-menopause with lower baseline remodeling rates may see slower gains.

Body Weight and Oral Bioavailability

Alendronate's oral bioavailability is already low at approximately 0.6 to 0.7% under fasting conditions. Women with lower body weight have proportionally less absolute drug absorbed per dose. The 70 mg weekly dose was designed for the general post-menopausal population, not weight-adjusted, but women with body weight below 50 kg may warrant closer attention to adherence to fasting administration instructions to maximize whatever absorption occurs. No weight-based dose adjustment is approved or studied in RCT data.

GI Tolerability and Female-Pattern Anatomy

Upper GI adverse effects (esophageal irritation, dysphagia, heartburn, nausea) are the most common reason women stop alendronate. These are not purely sex-specific, but women are overrepresented among alendronate discontinuers in real-world data, partly because gastroesophageal reflux is more prevalent in post-menopausal women whose lower esophageal sphincter tone declines with falling estrogen.

For treatment-experienced women who stopped their first course due to GI intolerance, oral rechallenge with attention to strict administration technique (full glass of water, upright position for 30 minutes, no food) resolves the issue in some, but not all, cases. Intravenous zoledronic acid (Reclast, 5 mg once yearly) is a reasonable alternative for women who cannot tolerate oral bisphosphonates.

Concomitant Hormone Therapy

Adding alendronate on top of MHT produces additive BMD gains at the spine and hip compared with either agent alone, as shown in the Women's Health Initiative hormone trials and the Alendronate/Estrogen study. The combination is not universally recommended but may be appropriate for high-risk post-menopausal women who are already on MHT for vasomotor symptoms and still have very low T-scores.

Pregnancy, Lactation, and Contraception: Required Reading

Alendronate is contraindicated in pregnancy. Stop here if you are pregnant or actively trying to conceive.

Pregnancy

Alendronate is FDA Pregnancy Category X (historical categorization; under the current Pregnancy and Lactation Labeling Rule, the label states that based on animal data and the mechanism of action, alendronate may cause fetal harm). Bisphosphonates accumulate in fetal bone because hydroxyapatite is actively being deposited throughout skeletal development. Animal studies showed skeletal malformations at doses equivalent to human exposure.

Human data is limited to case series and pharmacovigilance reports, not controlled trials. A systematic review of bisphosphonate exposure in pregnancy found no clear signal of teratogenicity in the small number of reported human pregnancies, but the data is far too sparse to reassure. Given the drug's long skeletal retention (estimated terminal half-life of over 10 years), bisphosphonate that was taken years before conception may still be mobilized from bone during the increased bone turnover of pregnancy and cross the placenta.

Practical guidance: Any woman of reproductive age who is prescribed alendronate should use reliable contraception for the duration of therapy and discuss the long skeletal half-life with her prescriber before attempting conception, even after stopping the drug. This conversation should happen at prescription initiation, not as an afterthought.

Lactation

There are no adequate data on alendronate transfer into human breast milk. Given the drug's poor oral bioavailability, even if some drug were present in milk, infant absorption may be negligible due to binding by calcium in milk. However, the FDA label advises caution and states that a decision should be made whether to discontinue nursing or discontinue the drug. For most lactating women, osteoporosis treatment is not an emergency; a decision to defer resumption of alendronate until weaning is reasonable in most cases. Women with severe postpartum osteoporosis (a rare condition) require specialist input and individualized decision-making.

Postpartum

Postpartum and lactation are themselves associated with transient bone loss of 3 to 5% at the hip, which recovers spontaneously in most women after weaning. Bisphosphonate use during this recovery period is rarely indicated and generally deferred.

Who This Is Right For, and Who Should Pause

Women Who Are Good Candidates for Alendronate (Drug-Naive)

• Post-menopausal women with a DXA T-score at or below -2.5 at any site
• Post-menopausal women with T-score between -1.0 and -2.5 and a 10-year FRAX major osteoporotic fracture probability at or above 20% (or hip fracture probability at or above 3%)
• Women aged 50+ with a low-trauma fragility fracture regardless of T-score
• Premenopausal women with glucocorticoid-induced osteoporosis (specialist-directed, off-label in some cases)

Women Who Should Not Start or Should Delay Alendronate

• Pregnant women or women actively trying to conceive
• Women with hypocalcemia (must correct before starting)
• Women with estimated GFR below 35 mL/min/1.73m² (not recommended; FDA label)
• Women with abnormalities of the esophagus that delay emptying (achalasia, stricture)
• Women unable to stand or sit upright for at least 30 minutes after dosing

Treatment-Experienced Women Who Should Not Resume

• Women who experienced an atypical femoral fracture on prior bisphosphonate therapy
• Women who developed confirmed ONJ on prior bisphosphonate therapy
• Women currently pregnant or planning pregnancy imminently

Monitoring: What a "Good Response" Looks Like at Each Stage

DEXA timing and interpretation differ by treatment history.

Drug-Naive Monitoring Schedule

• Baseline DEXA before starting
• Repeat DEXA at 1 to 2 years to confirm response
• If T-score has improved to above -2.0 at all sites and no new fractures, continue therapy and recheck at 2-year intervals
• Bone turnover markers (serum CTX or urine NTX) can be checked at 3 to 6 months to confirm biochemical response before the DEXA, because CTX suppression of 25 to 50% from baseline is the expected early signal

Treatment-Experienced (Restart) Monitoring Schedule

• DEXA at restart (establish new baseline after holiday)
• Repeat DEXA at 2 years
• Bone turnover markers at 3 to 6 months after restart, understanding that the degree of CTX suppression may be attenuated compared to the first course due to residual drug
• Consider reassessing the need for anabolic therapy (teriparatide, abaloparatide, romosozumab) if T-score continues to decline despite restart

As WomanRx reviewer Dr. Rachel Goldberg, OB-GYN, notes: "One of the most common clinical errors I see is interpreting a modest BMD gain on alendronate restart as drug failure, when in fact the patient's skeletal reservoir is still carrying residual drug from her first course. Context is everything. A woman who had 8% lumbar spine gain in her first three years and now shows 2% in year one of restart is not failing therapy. She is starting from a different biological baseline."

Calcium, Vitamin D, and the Drugs That Interfere

Alendronate's already-limited oral absorption is further reduced by calcium, antacids, iron supplements, and most other oral medications. All of these should be taken at least 30 to 60 minutes after the alendronate dose. Women who take morning calcium with breakfast and then try to fit in their alendronate will blunt absorption significantly.

Adequate calcium and vitamin D are prerequisites, not optional add-ons, for bisphosphonate efficacy. Without sufficient substrate for bone mineralization, alendronate can paradoxically worsen osteomalacia in women with severe vitamin D deficiency. Current recommendations are 1,200 mg/day of elemental calcium from food and supplements combined for post-menopausal women, and 800 to 2,000 IU/day of vitamin D3, with serum 25-hydroxyvitamin D maintained above 30 ng/mL.

Check 25-hydroxyvitamin D before starting alendronate in any drug-naive or restarting treatment-experienced woman. Correcting deficiency before the first dose is not a delay; it is standard of care.